High-risk Locally Advanced Prostate Cancer: Multimodal Treatment Is the Key

Affiliations

Mario Terlizzi et al. Eur Urol Open Sci. 2022.

. 2022 Feb 10:38:14-16.

doi: 10.1016/j.euros.2021.07.010. eCollection 2022 Apr.

¹ Radiation Therapy Department and Brachytherapy Unit, Institut Gustave Roussy, Villejuif, France.

No abstract available

References

1. Chang A.J., Autio K.A., Roach M., Scher H.I. High-risk prostate cancer—classification and therapy. Nat Rev Clin Oncol. 2014;11:308–323. - PMC - PubMed
1. Soloway M., Roach M. Prostate cancer progression after therapy of primary curative intent: a review of data from prostate-specific antigen era. Cancer. 2005;104:2310–2322. - PubMed
1. Wang Z., Ni Y., Chen J., et al. The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis. World J Surg Oncol. 2020;18:42. - PMC - PubMed
1. Kishan A.U., Cook R.R., Ciezki J.P., et al. Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9–10 prostate cancer. JAMA. 2018;319:896–905. - PMC - PubMed
1. Zelefsky M.J., Eastham J.A., Cronin A.M., et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol. 2010;28:1508–1513. - PMC - PubMed